MA40897B1 - Unité de dispositif de médicaments contenant de la quinagolide - Google Patents

Unité de dispositif de médicaments contenant de la quinagolide

Info

Publication number
MA40897B1
MA40897B1 MA40897A MA40897A MA40897B1 MA 40897 B1 MA40897 B1 MA 40897B1 MA 40897 A MA40897 A MA 40897A MA 40897 A MA40897 A MA 40897A MA 40897 B1 MA40897 B1 MA 40897B1
Authority
MA
Morocco
Prior art keywords
drug
quinagolide
device unit
poly
alkylene oxide
Prior art date
Application number
MA40897A
Other languages
English (en)
Other versions
MA40897A (fr
Inventor
Janet Halliday
Denis Carr
Alistair Ross
Claire Young
Paul Mcdonald
Mohammad Qadir
Robert Cochrane
Gouher Rabani
Axel Niclas Petri
Saez Joan Carles Arce
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51951583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40897(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MA40897A publication Critical patent/MA40897A/fr
Publication of MA40897B1 publication Critical patent/MA40897B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C48/00—Extrusion moulding, i.e. expressing the moulding material through a die or nozzle which imparts the desired form; Apparatus therefor
    • B29C48/001—Combinations of extrusion moulding with other shaping operations
    • B29C48/0021—Combinations of extrusion moulding with other shaping operations combined with joining, lining or laminating
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2033/00—Use of polymers of unsaturated acids or derivatives thereof as moulding material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035—Medical or pharmaceutical agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00—Other particular articles
    • B29L2031/753—Medical equipment; Accessories therefor
    • B29L2031/754—Pessaries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention est basée sur l'identification d'une cohorte de copolymères séquencés de polyuréthane qui sont particulièrement adaptés pour utilisation dans des unités médicament-dispositif polymères pharmaceutiques et qui permettent un contrôle amélioré de la libération de médicament. En particulier, l'invention concerne une unité médicament-dispositif polymère comprenant un copolymère séquencé de polyuréthane pouvant être obtenu par réaction conjointement d'un poly(oxyde d'alkylène) ; un composé difonctionnel ; un isocyanate difonctionnel ; et facultativement un copolymère séquencé comprenant des blocs de poly(oxyde d'alkylène) ; et du quinagolide en tant qu'agent actif pharmaceutique. Les unités médicament-dispositif peuvent avoir une application dans le traitement et/ou la prévention de l'endométriose.
MA40897A 2014-11-07 2015-11-05 Unité de dispositif de médicaments contenant de la quinagolide MA40897B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14192372.2A EP3017809A1 (fr) 2014-11-07 2014-11-07 Unité de dispositif de médicaments contenant de la quinagolide
PCT/EP2015/075849 WO2016071466A1 (fr) 2014-11-07 2015-11-05 Unité médicament-dispositif contenant du quinagolide

Publications (2)

Publication Number Publication Date
MA40897A MA40897A (fr) 2017-09-13
MA40897B1 true MA40897B1 (fr) 2021-04-30

Family

ID=51951583

Family Applications (2)

Application Number Title Priority Date Filing Date
MA056414A MA56414A (fr) 2014-11-07 2015-11-05 Unité de dispositif de médicaments contenant de la quinagolide
MA40897A MA40897B1 (fr) 2014-11-07 2015-11-05 Unité de dispositif de médicaments contenant de la quinagolide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA056414A MA56414A (fr) 2014-11-07 2015-11-05 Unité de dispositif de médicaments contenant de la quinagolide

Country Status (34)

Country Link
US (2) US20180008535A1 (fr)
EP (3) EP3017809A1 (fr)
JP (2) JP6907120B2 (fr)
KR (1) KR102612852B1 (fr)
CN (2) CN106999422A (fr)
AR (1) AR102571A1 (fr)
AU (2) AU2015341734C1 (fr)
CA (1) CA2966473A1 (fr)
CL (1) CL2017001119A1 (fr)
CO (1) CO2017005578A2 (fr)
DK (1) DK3215118T3 (fr)
EA (2) EA033806B9 (fr)
ES (1) ES2877973T3 (fr)
HR (1) HRP20210961T1 (fr)
HU (1) HUE054951T2 (fr)
IL (1) IL252088B (fr)
JO (1) JO3561B1 (fr)
LT (1) LT3215118T (fr)
MA (2) MA56414A (fr)
MD (1) MD3215118T2 (fr)
MX (1) MX379298B (fr)
MY (1) MY193638A (fr)
NZ (1) NZ731763A (fr)
PH (1) PH12017550005A1 (fr)
PL (1) PL3215118T3 (fr)
PT (1) PT3215118T (fr)
RS (1) RS62018B1 (fr)
SA (1) SA517381471B1 (fr)
SG (1) SG11201703596SA (fr)
SI (1) SI3215118T1 (fr)
TN (1) TN2017000175A1 (fr)
TW (1) TWI685339B (fr)
UA (1) UA122329C2 (fr)
WO (1) WO2016071466A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11896685B2 (en) 2018-10-31 2024-02-13 Amorepacific Corporation Core-shell network structure comprising biopolymer and composition comprising same
KR102936013B1 (ko) 2019-12-03 2026-03-10 (주)아모레퍼시픽 바이오 폴리머를 포함하는 효능물질 전달체
EP4395751A1 (fr) 2021-08-31 2024-07-10 Ferring B.V. Diagnostic et traitement de l'endométriose ectopique
WO2024153752A1 (fr) 2023-01-20 2024-07-25 Ferring B.V. Synthèse stéréosélective d'intermédiaires et synthèse de quinagolides
TW202528403A (zh) * 2023-10-31 2025-07-16 德商巴斯夫歐洲公司 用於製造熱塑性聚氨酯之方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235988A (en) 1976-12-13 1980-11-25 Imperial Chemical Industries Limited Delivery means for biologically active agents
EP1620060B1 (fr) 2003-04-29 2010-03-24 The General Hospital Corporation Procedes et dispositifs a liberation soutenue de plusieurs medicaments
CA2531640C (fr) 2003-07-10 2013-06-18 Galen (Chemicals) Limited Dispositifs d'administration de medicaments par voie intravaginale
EP1682102A2 (fr) * 2003-09-10 2006-07-26 Noven Pharmaceuticals, Inc. Dispositif multicouche d'administration transdermique de medicaments
WO2006117608A1 (fr) 2005-04-29 2006-11-09 Ferring International Center S.A. Traitement ou prevention du syndrome d'hyperstimulation ovarienne (ohss) au moyen d'un agoniste de la dopamine
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
SA08290041B1 (ar) 2007-02-01 2012-06-05 فيرينج انترناشونال سنتر اس آيه أدوية من أجل معالجة بطانة الرحم
US20110045076A1 (en) 2008-01-25 2011-02-24 Kiser Patrick F Linear order release polymer
WO2009092601A1 (fr) * 2008-01-25 2009-07-30 Grünenthal GmbH Forme posologique pharmaceutique
US20100040671A1 (en) 2008-08-12 2010-02-18 Ahmed Salah U Intravaginal Devices With a Rigid Support, Methods of Making, and Uses Thereof
US20100210600A1 (en) * 2009-02-19 2010-08-19 Prelief Inc. Methods and Compositions for Treating Urogenital Disorders
EP2445501A2 (fr) * 2009-06-26 2012-05-02 Ferring B.V. Utilisation de la quinagolide pour le traitement de l'endométriose, du cancer et de la douleur
WO2011127405A1 (fr) * 2010-04-08 2011-10-13 Sanford-Burnham Medical Research Institute Méthodes et compositions pour une administration améliorée de composés
ES2728975T3 (es) 2010-11-15 2019-10-29 Dsm Ip Assets Bv Dispositivo intravaginal de aporte de fármacos que comprende un copolímero de poliuretano
CA2842550C (fr) * 2011-07-20 2020-03-24 Patrick F. Kiser Dispositifs intravaginaux pour administration de medicaments
US10137199B2 (en) * 2013-05-14 2018-11-27 Biotime, Inc. Thiolated hyaluronan-based hydrogels cross-linked using oxidized glutathione
US10413504B2 (en) * 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system

Also Published As

Publication number Publication date
CA2966473A1 (fr) 2016-05-12
MD3215118T2 (ro) 2021-08-31
EA201790898A1 (ru) 2017-11-30
EA033806B1 (ru) 2019-11-27
MX379298B (es) 2025-03-10
SI3215118T1 (sl) 2021-08-31
EP3017809A1 (fr) 2016-05-11
US20220040094A1 (en) 2022-02-10
EA201991882A2 (ru) 2020-01-31
AU2020270480A1 (en) 2020-12-17
MX2017005828A (es) 2017-11-13
NZ731763A (en) 2024-04-26
RS62018B1 (sr) 2021-07-30
PT3215118T (pt) 2021-05-31
UA122329C2 (uk) 2020-10-26
HRP20210961T1 (hr) 2021-09-17
TN2017000175A1 (en) 2018-10-19
US20180008535A1 (en) 2018-01-11
CL2017001119A1 (es) 2018-01-05
MA56414A (fr) 2022-05-04
EA201790898A8 (ru) 2018-01-31
JO3561B1 (ar) 2020-07-05
JP2017533272A (ja) 2017-11-09
AU2015341734A1 (en) 2017-06-01
JP6907120B2 (ja) 2021-07-21
IL252088A0 (en) 2017-07-31
EP3215118B1 (fr) 2021-03-17
CN116212032A (zh) 2023-06-06
CN106999422A (zh) 2017-08-01
AU2015341734B2 (en) 2020-08-20
HUE054951T2 (hu) 2021-10-28
EP3892261A1 (fr) 2021-10-13
SA517381471B1 (ar) 2022-03-06
KR102612852B1 (ko) 2023-12-11
WO2016071466A1 (fr) 2016-05-12
BR112017009476A2 (en) 2018-01-02
ES2877973T3 (es) 2021-11-17
PL3215118T3 (pl) 2021-07-26
LT3215118T (lt) 2021-06-10
JP2021155444A (ja) 2021-10-07
EA033806B9 (ru) 2019-12-19
TWI685339B (zh) 2020-02-21
CO2017005578A2 (es) 2017-08-31
IL252088B (en) 2022-04-01
AR102571A1 (es) 2017-03-08
KR20170080671A (ko) 2017-07-10
DK3215118T3 (da) 2021-06-21
EP3215118A1 (fr) 2017-09-13
AU2015341734C1 (en) 2020-12-17
MA40897A (fr) 2017-09-13
TW201625245A (zh) 2016-07-16
MY193638A (en) 2022-10-21
SG11201703596SA (en) 2017-06-29
PH12017550005A1 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
MA40897B1 (fr) Unité de dispositif de médicaments contenant de la quinagolide
MA43335B1 (fr) Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr
TN2019000126A1 (fr) Nouvelles compositions antivirales pour le traitement des infections liées aux coronavirus.
MA41197B1 (fr) Traitement de le pemphigus
MA37809A1 (fr) Administration de médicament biodégradable pour compositions hydrophobes
EP3893776A4 (fr) Distracteurs ayant des palettes pouvant être fixées, dispositifs d'impaction et procédés pour une utilisation dans le remplacement total de la cheville
PE20061087A1 (es) Formas farmaceuticas resistente a la rotura con liberacion sostenida
EP3965772A4 (fr) Composition pharmaceutique à base de brexanolone, de ganaxolone ou de zuranolone, et son utilisation
BR112022002289A2 (pt) Composições de curativo líquido e seus usos veterinários
EP3675346A4 (fr) Dispositif d'entraînement de charge, dispositif à semiconducteur, système d'entraînement de charge et véhicule
FR3065371B1 (fr) Composition pharmaceutique topique comprenant au moins de l'amitriptyline pour le traitement de douleurs neuropathiques peripheriques
FR3044663B1 (fr) Copolymere monofonctionnel ou telechelique de 1,3-butadiene et d'ethylene.
MX2022007285A (es) Compuestos, polimeros, dispositivos y usos de los mismos.
WO2015126930A3 (fr) Pharmacothérapie à effet "booster" pour lutter contre les infections à mycobacterium
EP3902506A4 (fr) Procédés et dispositifs pour empêcher la naissance prématurée, la mortinaissance, la fausse-couche, l'infection ou la grossesse
EP3904518A4 (fr) Composition pharmaceutique pour la prévention ou le traitement du cancer, comprenant un modulateur d'expression tut4/7
MA54936A (fr) Triamtérène ou nolatrexed destinés à être utilisés dans le traitement de la phénylcétonurie
UA114469C2 (uk) Фармацевтична композиція, що містить протимікробний агент
BR112015023114A2 (pt) copolímeros de bloco acrílicos
EP3881855A4 (fr) Composition pour prévenir ou traiter une inflammation, des allergies et de l'asthme, contenant veronicastrum sibiricum l. pennell en tant que principe actif, et son utilisation
MA38871B2 (fr) Complexe lubrifiant pour la bouche
CL2022001355A1 (es) Uso de un anticuerpo inhibidor de masp-2, o un fragmento del mismo, para el tratamiento del síndrome de neumonía idiopática posterior a un trasplante de células madres hematopoyéticas (hsct-ips).
SA119410171B1 (ar) طريقة لمنع أو علاج أو تحسين عدوى ميكروبية
EP3783141C0 (fr) Ensemble de distribution d'agent de traitement de vêtements destiné à être utilisé dans un dispositif de traitement de vêtements, et dispositif de traitement de vêtements
EP4056188A4 (fr) Agent pour la prévention ou le traitement d'une arythmie et dispositif pour la prévention ou le traitement d'une arythmie